TrialClinical rheumatology2019

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.

Christopher J Edwards et al.PubMed ↗Publisher ↗

No numbers read from the abstract.